Drug Discovery Services Market by Process (Target Selection, Validation, Lead Optimization), Type (Medicinal Chemistry, DMPK), Drug Type (Biologics, Small Molecules), Therapeutic (Oncology, Neurology), Company (Tier 1, 2, 3) - Global Forecast to 2025

創薬サービスの世界市場予測:プロセス別(ターゲット選択、検証、リード最適化)、種類別(医薬品化学、DMPK)、薬物タイプ別(生物製剤、小分子)、治療別(腫瘍学、神経学)、企業別(ティア1、2、3)

◆タイトル:Drug Discovery Services Market by Process (Target Selection, Validation, Lead Optimization), Type (Medicinal Chemistry, DMPK), Drug Type (Biologics, Small Molecules), Therapeutic (Oncology, Neurology), Company (Tier 1, 2, 3) - Global Forecast to 2025
◆商品コード:PH 5682
◆調査・発行会社:MarketsandMarkets
◆発行日:2020年1月31日
◆ページ数:170
◆レポート形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:医薬品
◆販売価格オプション(消費税別)
Single User(1名様閲覧)USD5,650 ⇒換算¥610,200見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算¥718,200見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD8,150 ⇒換算¥880,200見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、レポートに記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はMarketsandMarketsの日本における正規販売代理店です。

【レポートの概要】

MarketsandMarkets社は創薬サービスの世界市場が、2020年107億ドルから2025年191憶ドルまで、年平均12.1%成長すると予測しています。本調査レポートでは、創薬サービスの世界市場について調査・分析し、イントロダクション、調査手法、エグゼクティブサマリー、プレミアムインサイト、市場動向、業界洞察、プロセス別(ターゲット選択、ターゲット検証、ヒットトゥリード識別、リード最適化)分析、種類別(医薬品化学サービス、生物学サービス、DMPK)分析、薬物タイプ別(生物製剤、小分子)分析、治療領域別(腫瘍学、神経学、感染性及び免疫系疾患、消化器系疾患)分析、企業別(ティア1、2、3)分析、地域別分析、競争状況、企業概要などを含め、次の構成でお届け致します。
・イントロダクション
・調査手法
・エグゼクティブサマリー
・プレミアムインサイト
・市場動向
・創薬サービスの世界市場:プロセス別(ターゲット選択、ターゲット検証、ヒットトゥリード識別、リード最適化)
・創薬サービスの世界市場:種類別(医薬品化学サービス、生物学サービス、DMPK)
・創薬サービスの世界市場:薬物タイプ別(生物製剤、小分子)
・創薬サービスの世界市場:治療領域別(腫瘍学、神経学、感染性及び免疫系疾患、消化器系疾患)
・創薬サービスの世界市場:企業別(ティア1、2、3)
・創薬サービスの世界市場:地域別
・競争状況
・企業概要

“Drug discovery services market to register a CAGR of 12.1% from 2020 to 2025.”
The global drug discovery services market is projected to reach USD 19.1 billion by 2025 from USD 10.7 billion in 2020, at a CAGR of 12.1% from 2020 to 2025. The growth of the industry is driven primarily by factors such as growing R&D expenditure in the pharmaceutical & biopharmaceutical industry, increasing demand for outsourcing analytical testing and clinical trial services, initiatives for research on rare diseases and orphan drugs, and focus on drug discovery. Growth in the biologics market and patent expiries will further provide opportunities in the drug discovery services industry. Developing economies are expected to offer a wide range of growth opportunities for players in the market.

“The Hit-to-Lead process segment is anticipated to grow at the fastest growth rate during the forecast period.”
Based on the process, the drug discovery services market is segmented into target selection, target validation, hit-to-lead identification, lead optimization, and candidate validation. Hit-to-lead identification process is anticipated to be the fastest-growing segment due to the high outsourcing of these services to CROs by the pharmaceutical companies and the emerging advanced technologies for high-throughput screening (HTS) and H2L as well as reductions in development time.

“Medicinal Chemistry segment is estimated to account for the largest share of the drug discovery services market in 2020.”
Based on type, the drug discovery services market is segmented into medicinal chemistry services, biology services, and drug metabolism and pharmacokinetics (DMPK). The medicinal chemistry services segment is estimated to account for the largest share of the drug discovery services market due to the widespread application of medicinal chemistry in various phases of preclinical drug discovery to deliver robust candidates.

“Oncology segment is anticipated to grow at the fastest growth rate during the forecast period.”
Based on the therapeutic area, the drug discovery services market is segmented into oncology, cardiovascular diseases, neurology, infectious and immune system diseases, digestive system diseases, and other therapeutic areas. Of all these therapeutic segments, oncology will grow at the fastest CAGR in the drug discovery services market in 2019. The high growth of the oncology segment can be attributed to factors such as the increasing number of patients who have cancer, the subsequent increase in the demand for cancer therapies and the growing R&D expenditure by pharmaceutical companies in this therapeutic area.

“North America is expected to dominate the drug discovery services market in 2020.”
North America, which includes the US and Canada, is estimated to account for the largest share of the drug discovery services market. The large share of this region can primarily be attributed to the presence of well-established CROs; rising R&D expenditure by pharmaceutical & biopharmaceutical companies and the availability of latest techniques, instruments, and facilities for drug discovery research are driving the growth of this region.

Breakdown of supply-side primary interviews, by company type, designation, and region:
• By Company Type: Tier 1 (40%) , Tier 2 (30%), and Tier 3 (30%)
• By Designation: C-level (27%), Director-level (18%), and Others (55%)
• By Region: North America (50%), Europe (20%), Asia Pacific (20%), and RoW (10%)

The key players operating in this market include Thermo Fisher Scientific, Inc. (US), Albany Molecular Research, Inc. (US), Charles River Laboratories International, Inc. (US), Evotec SE (Germany), Eurofins Scientific (Luxembourg), WuXi AppTec (China), GenScript Biotech Corporation (China), Jubilant Life Sciences (India), Laboratory Corporation of America Holdings (US), Piramal Enterprises Ltd. (India), Viva Biotech (China), Domainex (UK), Shanghai Medicilon, Inc. (China), TCG Lifesciences Pvt. Limited (India), Frontage Holdings (US), Pharmaceutical Product Development, LLC (US), Syngene International Ltd. (India), ChemPartner Co., Ltd (China), Aurigene Discovery Technologies Limited (A subsidiary of Dr. Reddy’s, Laboratories) (India), and Selvita S.A. (Poland). Services launches, expansions, collaborations, agreements, partnerships and acquisitions are the key growth strategies followed by most players in this market.

Research Coverage
This report studies the drug discovery services market based on the process, type, drug type, therapeutic area, company type, and region. The report also analyzes factors (such as drivers, restraints, opportunities, and trends) affecting market growth. It evaluates the opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders. The report also studies micro-markets concerning their growth trends, prospects, and contributions to the total drug discovery services market. The report forecasts the revenue of the market segments concerning four major regions.

Reasons to Buy the Report:
The report provides insights on the following pointers:
• Market Penetration: Comprehensive information on the drug discovery services offered by the key 20 players in the drug discovery services market. The report analyzes the drug discovery services market by process, type, drug type, therapeutic area, company type, and region.
• Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various drug discovery services, their adoption, type of applications across key geographic regions.
• Market Diversification: Exhaustive information about new services, untapped geographies, recent developments, and investments in the drug discovery services market
• Competitive Assessment: In-depth assessment of market shares and strategies of the leading players in the drug discovery services market along with a competitive leadership mapping of up to 25 players in the market.

【レポートの目次】

1 Introduction (Page No. – 19)
1.1 Objectives of the Study
1.2 Market Definition
1.3 Market Scope
1.3.1 Markets Covered
1.3.2 Years Considered for the Study
1.4 Currency
1.5 Limitations
1.6 Stakeholders

2 Research Methodology (Page No. – 22)
2.1 Research Data
2.1.1 Secondary Data
2.1.1.1 Key Data From Secondary Sources
2.1.2 Primary Data
2.2 Market Size Estimation
2.2.1 Market Size Estimation: Bottom-Up Approach
2.2.2 Market Size Estimation: Top-Down Approach
2.2.3 Growth Forecast
2.3 Market Breakdown and Data Triangulation
2.4 Assumptions for the Study

3 Executive Summary (Page No. – 29)

4 Premium Insights (Page No. – 33)
4.1 Drug Discovery Services Market Overview
4.2 North America: Market, By Drug Type & Country (2020)
4.3 Market: Geographic Growth Opportunities

5 Market Overview (Page No. – 36)
5.1 Introduction
5.2 Market Dynamics
5.2.1 Drivers
5.2.1.1 Growing R&D Expenditure in the Pharmaceutical & Biopharmaceutical Industry
5.2.1.2 Increasing Demand for Outsourcing Analytical Testing and Clinical Trial Services
5.2.1.3 Initiatives for Research on Rare Diseases and Orphan Drugs
5.2.1.4 Focus on Drug Discovery
5.2.2 Restraints
5.2.2.1 High Cost of Drug Discovery and Development
5.2.2.2 Stringent Regulations Governing Drug Discovery and Animal Usage
5.2.3 Opportunities
5.2.3.1 Growth in the Biologics Market
5.2.3.2 Patent Expiries
5.2.3.3 Emerging Markets
5.2.4 Trends
5.2.4.1 Growing Adoption of Artificial Intelligence-Based Tools for Drug Discovery

6 Drug Discovery Services Market, By Process (Page No. – 47)
6.1 Introduction
6.2 Target Selection
6.2.1 Increasing Demand for Personalized Medicine to Support the Growth of This Market
6.3 Target Validation
6.3.1 Rising Number of Drug Discovery Research Activities to Support Market Growth
6.4 Hit-To-Lead Identification
6.4.1 Hit-To-Lead Identification is the Largest Process Segment in the Market
6.5 Lead Optimization
6.5.1 Lead Optimization Requires State-Of-The-Art Informatics Systems to Facilitate Transparent Presentation and Analysis
6.6 Candidate Validation
6.6.1 Candidate Validation Segment to Grow at a High CAGR During the Forecast Period

7 Drug Discovery Services Market, By Type (Page No. – 53)
7.1 Introduction
7.2 Medicinal Chemistry Services
7.2.1 Wide Applications of Medicinal Chemistry in Drug Discovery are a Major Factor Driving Market Growth
7.3 Biology Services
7.3.1 Restrictions on the Usage of Animals in Research Activities May Limit Market Growth
7.4 Drug Metabolism & Pharmacokinetics
7.4.1 DMPK Studies are Employed at the Discovery, Candidate Selection, Investigational New Drug, and New Drug Application Stages

8 Drug Discovery Services Market, By Drug Type (Page No. – 57)
8.1 Introduction
8.2 Small-Molecule Drugs
8.2.1 Increasing Number of Start-Ups and New Entrants in the Small-Molecule Drugs Segment Will Drive the Growth of This Market During the Forecast Period
8.3 Biologic Drugs
8.3.1 High Set-Up Costs of the Instruments Required for Biologic Drug Manufacturing May Limit Market Growth to a Certain Extent

9 Drug Discovery Services Market, By Therapeutic Area (Page No. – 61)
9.1 Introduction
9.2 Oncology
9.2.1 High and Growing Number of Research Studies on Cancer Therapeutics to Support Market Growth
9.3 Neurology
9.3.1 Increasing Number of Patients Suffering From Neurological Disorders is Driving Market Growth
9.4 Infectious and Immune System Diseases
9.4.1 Emergence of New Infectious Diseases to Drive Market Growth
9.5 Digestive System Diseases
9.5.1 as There is a Huge Population Seeking Effective Remedies for Digestive Diseases, Pharmaceutical Companies are Investing Significantly in R&D for the Development of Innovative Drugs
9.6 Cardiovascular Diseases
9.6.1 High Global Burden of Cardiovascular Diseases has Increased the Focus on Developing Effective Drugs
9.7 Other Therapeutic Areas

10 Drug Discovery Services Market, By Company Type (Page No. – 70)
10.1 Introduction
10.2 Tier 1 Pharmaceutical Companies
10.3 Tier 2 Pharmaceutical Companies
10.4 Tier 3 Pharmaceutical Companies

11 Drug Discovery Services Market, By Region (Page No. – 73)
11.1 Introduction
11.2 North America
11.2.1 US
11.2.1.1 Availability of Advanced R&D Infrastructure has Driven the Growth of the US Market
11.2.2 Canada
11.2.2.1 Preference of Pharmaceutical Companies to Conduct Clinical Trials in Canada to Support Market Growth
11.3 Europe
11.3.1 Germany
11.3.1.1 Government Support and Flexible Labor Laws are Driving the Growth of the German Market
11.3.2 UK
11.3.2.1 Investment By Pharmaceutical Sponsors in the UK for Drug Discovery Services to Support Market Growth
11.3.3 France
11.3.3.1 High Number of Oncology Clinical Trials in France to Drive Market Growth
11.3.4 Italy
11.3.4.1 High Number of Clinical Trials and the Low Drug Approval Time are the Major Factors Driving Market Growth
11.3.5 Spain
11.3.5.1 Short Study Start-Up Times and Rising R&D Expenditure to Boost the Growth of the Spanish Market
11.3.6 Rest of Europe
11.4 Asia Pacific
11.4.1 China
11.4.1.1 Low Cost of Clinical Trials and Large Pharmaceutical R&D Footprint in China to Drive Market Growth
11.4.2 India
11.4.2.1 Low-Cost Services and Availability of Skilled Workforce to Support Market Growth in India
11.4.3 Japan
11.4.3.1 Government Initiatives for Drug Innovation to Support Market Growth in Japan
11.4.4 Rest of Asia Pacific
11.5 Rest of the World

12 Competitive Landscape (Page No. – 117)
12.1 Overview
12.2 Market Share Analysis
12.3 Competitive Scenario
12.3.1 Partnerships, Agreements, and Collaborations
12.3.2 Service Launches
12.3.3 Mergers & Acquisitions
12.3.4 Expansions
12.4 Competitive Leadership Mapping
12.4.1 Visionary Leaders
12.4.2 Innovators
12.4.3 Dynamic Differentiators
12.4.4 Emerging Companies

13 Company Profiles (Page No. – 122)
13.1 Laboratory Corporation of America Holdings
13.1.1 Business Overview
13.1.2 Services Offered
13.1.3 Recent Developments
13.2 Eurofins Scientific Se
13.2.1 Business Overview
13.2.2 Services Offered
13.2.3 Recent Developments
13.2.4 MnM View
13.3 Charles River Laboratories International
13.3.1 Business Overview
13.3.2 Services Offered
13.3.3 Recent Developments
13.3.4 MnM View
13.4 Evotec SE
13.4.1 Business Overview
13.4.2 Services Offered
13.4.3 Recent Developments
13.5 Thermo Fisher Scientific
13.5.1 Business Overview
13.5.2 Services Offered
13.5.3 Recent Developments
13.5.4 MnM View
13.6 Albany Molecular Research, Inc.
13.6.1 Business Overview
13.6.2 Services Offered
13.6.3 Recent Developments
13.7 Syngene International Limited
13.7.1 Business Overview
13.7.2 Services Offered
13.7.3 Recent Developments
13.8 Jubilant Lifesciences
13.8.1 Business Overview
13.8.2 Services Offered
13.8.3 Recent Developments
13.9 Genscript Biotech Corporation
13.9.1 Business Overview
13.9.2 Services Offered
13.9.3 Recent Developments
13.10 Piramal Enterprises Limited
13.10.1 Business Overview
13.10.2 Services Offered
13.10.3 Recent Developments
13.11 Selvita S.A.
13.11.1 Business Overview
13.11.2 Services Offered
13.11.3 Recent Developments
13.12 Aurigene Discovery Technologies (A Subsidiary of Dr. Reddy’s Laboratories)
13.12.1 Business Overview
13.12.2 Services Offered
13.12.3 Recent Developments
13.13 Domainex Ltd.
13.13.1 Business Overview
13.13.2 Services Offered
13.13.3 Recent Developments
13.14 WuXi AppTec
13.14.1 Business Overview
13.14.2 Services Offered
13.14.3 Recent Developments
13.15 Chempartner Co., Ltd.
13.15.1 Business Overview
13.15.2 Services Offered
13.15.3 Recent Developments
13.16 Frontage Holdings
13.16.1 Business Overview
13.16.2 Services Offered
13.16.3 Recent Developments
13.17 Pharmaceutical Product Development, LLC
13.17.1 Business Overview
13.17.2 Services Offered
13.17.3 Recent Developments
13.18 Shanghai Medicilon, Inc.
13.19 TCG Lifesciences Pvt. Limited
13.20 Viva Biotech (Shanghai) Ltd.

14 Appendix (Page No. – 161)
14.1 Discussion Guide
14.2 Knowledge Store: Marketsandmarkets’ Subscription Portal
14.3 Available Customizations
14.4 Related Reports
14.5 Author Details

List of Tables (111 Tablese)

Table 1 Drug Discovery Process Overview
Table 2 Research Projects Funded By the Irdirc
Table 3 Average Cost of Drugs Approved Per Year, 2004–2013
Table 4 Drug Discovery Services Market, By Process, 2018–2025 (USD Million)
Table 5 Market for Target Selection, By Region, 2018–2025 (USD Million)
Table 6 Advantages and Disadvantages of Sirna
Table 7 Market for Target Validation, By Region, 2018–2025 (USD Million)
Table 8 Market for Hit-To-Lead Identification, By Region, 2018–2025 (USD Million)
Table 9 Market for Lead Optimization, By Region, 2018–2025 (USD Million)
Table 10 Market for Candidate Validation, By Region, 2018–2025 (USD Million)
Table 11 Market, By Type, 2018–2025 (USD Million)
Table 12 Medicinal Chemistry Drug Discovery Services Market, By Region, 2018–2025 (USD Million)
Table 13 Biology Drug Discovery Services Market, By Region, 2018–2025 (USD Million)
Table 14 DMPK Drug Discovery Services Market, By Region, 2018–2025 (USD Million)
Table 15 Market, By Drug Type, 2018–2025 (USD Million)
Table 16 Market for Small-Molecule Drugs, By Region, 2018–2025 (USD Million)
Table 17 Market for Biologic Drugs, By Region, 2018–2025 (USD Million)
Table 18 Global Number of Clinical Trials, By Therapeutic Area (As of October 2019)
Table 19 Market, By Therapeutic Area, 2018–2025 (USD Million)
Table 20 Market for Oncology, By Region, 2018–2025 (USD Million)
Table 21 Market for Neurology, By Region, 2018–2025 (USD Million)
Table 22 Market for Infectious and Immune System Diseases, By Region, 2018–2025 (USD Million)
Table 23 Market for Digestive System Diseases, By Region, 2018–2025 (USD Million)
Table 24 Market for Cardiovascular Diseases, By Region, 2018–2025 (USD Million)
Table 25 Market for Other Therapeutic Areas, By Region, 2018–2025 (USD Million)
Table 26 Market, By Company Type, 2018–2025 (USD Million)
Table 27 Market for Tier 1 Pharmaceutical Companies, By Region, 2018–2025 (USD Million)
Table 28 Market for Tier 2 Pharmaceutical Companies, By Region, 2018–2025 (USD Million)
Table 29 Market for Tier 3 Pharmaceutical Companies, By Region, 2018–2025 (USD Million)
Table 30 Market, By Region, 2018–2025 (USD Million)
Table 31 North America: Market, By Country, 2018–2025 (USD Million)
Table 32 North America: Market, By Process, 2018–2025 (USD Million)
Table 33 North America: Market, By Type, 2018–2025 (USD Million)
Table 34 North America: Drug Discovery Services Market, By Drug Type, 2018–2025 (USD Million)
Table 35 North America: Market, By Therapeutic Area, 2018–2025 (USD Million)
Table 36 North America: Market, By Company Type, 2018–2025 (USD Million)
Table 37 Number of Clinical Trials Started in the US, By Company, 2017
Table 38 US: Market, By Process, 2018–2025 (USD Million)
Table 39 US: Market, By Type, 2018–2025 (USD Million)
Table 40 US: Market, By Drug Type, 2018–2025 (USD Million)
Table 41 US: Market, By Therapeutic Area, 2018–2025 (USD Million)
Table 42 Number of Active Clinical Trials in Canada, By Condition (2019)
Table 43 Number of Active Clinical Trials in Canada, By Company, 2017
Table 44 Canada: Market, By Process, 2018–2025 (USD Million)
Table 45 Canada: Market, By Type, 2018–2025 (USD Million)
Table 46 Canada: Market, By Drug Type, 2018–2025 (USD Million)
Table 47 Canada: Market, By Therapeutic Area, 2018–2025 (USD Million)
Table 48 Europe: Market, By Country, 2018–2025 (USD Million)
Table 49 Europe: Market, By Process, 2018–2025 (USD Million)
Table 50 Europe: Market, By Type, 2018–2025 (USD Million)
Table 51 Europe: Market, By Drug Type, 2018–2025 (USD Million)
Table 52 Europe: Market, By Therapeutic Area, 2018–2025 (USD Million)
Table 53 Europe: Market, By Company Type, 2018–2025 (USD Million)
Table 54 Germany: Market, By Process, 2018–2025 (USD Million)
Table 55 Germany: Market, By Type, 2018–2025 (USD Million)
Table 56 Germany: Market, By Drug Type, 2018–2025 (USD Million)
Table 57 Germany: Market, By Therapeutic Area, 2018–2025 (USD Million)
Table 58 UK: Drug Discovery Services Market, By Process, 2018–2025 (USD Million)
Table 59 UK: Market, By Type, 2018–2025 (USD Million)
Table 60 UK: Market, By Drug Type, 2018–2025 (USD Million)
Table 61 UK: Market, By Therapeutic Area, 2018–2025 (USD Million)
Table 62 Number of Clinical Trials Started in France, By Company, 2017
Table 63 France: Market, By Process, 2018–2025 (USD Million)
Table 64 France: Market, By Type, 2018–2025 (USD Million)
Table 65 France: Market, By Drug Type, 2018–2025 (USD Million)
Table 66 France: Market, By Therapeutic Area, 2018–2025 (USD Million)
Table 67 Number of Clinical Trials Started in Italy, By Company, 2017
Table 68 Italy: Market, By Process, 2018–2025 (USD Million)
Table 69 Italy: Market, By Type, 2018–2025 (USD Million)
Table 70 Italy: Market, By Drug Type, 2018–2025 (USD Million)
Table 71 Italy: Market, By Therapeutic Area, 2018–2025 (USD Million)
Table 72 Spain: Market, By Process, 2018–2025 (USD Million)
Table 73 Spain: Market, By Type, 2018–2025 (USD Million)
Table 74 Spain: Market, By Drug Type, 2018–2025 (USD Million)
Table 75 Spain: Market, By Therapeutic Area, 2018–2025 (USD Million)
Table 76 RoE: Market, By Process, 2018–2025 (USD Million)
Table 77 RoE: Market, By Type, 2018–2025 (USD Million)
Table 78 RoE: Market, By Drug Type, 2018–2025 (USD Million)
Table 79 RoE: Market, By Therapeutic Area, 2018–2025 (USD Million)
Table 80 Total Number of Clinical Trials in APAC, By Therapeutic Area, 2017
Table 81 APAC: Market, By Country, 2018–2025 (USD Million)
Table 82 APAC: Market, By Process, 2018–2025 (USD Million)
Table 83 APAC: Market, By Type, 2018–2025 (USD Million)
Table 84 APAC: Market, By Drug Type, 2018–2025 (USD Million)
Table 85 APAC: Market, By Therapeutic Area, 2018–2025 (USD Million)
Table 86 APAC: Market, By Company Type, 2018–2025 (USD Million)
Table 87 China: Market, By Process, 2018–2025 (USD Million)
Table 88 China: Market, By Type, 2018–2025 (USD Million)
Table 89 China: Drug Discovery Services Market, By Drug Type, 2018–2025 (USD Million)
Table 90 China: Market, By Therapeutic Area, 2018–2025 (USD Million)
Table 91 India: Market, By Process, 2018–2025 (USD Million)
Table 92 India: Market, By Type, 2018–2025 (USD Million)
Table 93 India: Market, By Drug Type, 2018–2025 (USD Million)
Table 94 India: Market, By Therapeutic Area, 2018–2025 (USD Million)
Table 95 Japan: Market, By Process, 2018–2025 (USD Million)
Table 96 Japan: Market, By Type, 2018–2025 (USD Million)
Table 97 Japan: Market, By Drug Type, 2018–2025 (USD Million)
Table 98 Japan: Market, By Therapeutic Area, 2018–2025 (USD Million)
Table 99 RoAPAC: Market, By Process, 2018–2025 (USD Million)
Table 100 RoAPAC: Market, By Type, 2018–2025 (USD Million)
Table 101 RoAPAC: Market, By Drug Type, 2018–2025 (USD Million)
Table 102 RoAPAC: Market, By Therapeutic Area, 2018–2025 (USD Million)
Table 103 RoW: Market, By Process, 2018–2025 (USD Million)
Table 104 RoW: Market, By Type, 2018–2025 (USD Million)
Table 105 RoW: Market, By Drug Type, 2018–2025 (USD Million)
Table 106 RoW: Market, By Therapeutic Area, 2018–2025 (USD Million)
Table 107 RoW: Market, By Company Type, 2018–2025 (USD Million)
Table 108 Partnerships, Agreements, and Collaborations (2017–2019)
Table 109 Service Launches (2017–2019)
Table 110 Mergers & Acquisitions (2017–2019)
Table 111 Expansions (2017–2019)

List of Figures (39 Figures)

Figure 1 Drug Discovery Services Market Segmentation
Figure 2 Research Design
Figure 3 Breakdown of Primary Interviews: By Company Type, Designation, and Region
Figure 4 Bottom-Up Approach
Figure 5 Top-Down Approach
Figure 6 Data Triangulation Methodology
Figure 7 Market, By Process, 2020 Vs. 2025 (USD Million)
Figure 8 Market, By Type, 2020 Vs. 2025 (USD Million)
Figure 9 Market, By Drug Type, 2020 Vs. 2025 (USD Million)
Figure 10 Market, By Therapeutic Area, 2020 Vs. 2025 (USD Million)
Figure 11 Market, By Region, 2020 Vs. 2025 (USD Million)
Figure 12 Increasing R&D Expenditure in the Pharmaceutical & Biotechnology Industry to Drive Market Growth
Figure 13 Small-Molecule Drugs to Account for the Largest Share of the North American Market in 2020
Figure 14 China to Register the Highest Growth in the Drug Discovery Services Market During the Forecast Period
Figure 15 Market: Drivers, Restraints, and Opportunities
Figure 16 R&D Spending of Phrma Member Companies, 2001–2017 (USD Billion)
Figure 17 Active Pharmaceutical Pipeline, January 2009–January 2019
Figure 18 Number of Orphan Indications Approved in the US (2010–2017)
Figure 19 Number of Registered Studies (2005–2017)
Figure 20 Average Cost to Develop One New Approved Drug—Including the Cost of Failures
Figure 21 R&D Pipeline, By Therapy Group, 2018 & 2019
Figure 22 Total Number of Clinical Trials for Oncology, By Region (As of December 2019)
Figure 23 Total Number of Clinical Trials: Global Vs. North America
Figure 24 North America: Market Snapshot
Figure 25 US: Pipeline Split of Pharmaceutical and Biotechnology Companies, By Phase (January 2019)
Figure 26 UK: Pharmaceutical R&D Expenditure, 2013–2017
Figure 27 Spain: Pharmaceutical R&D Expenditure, 2011–2017
Figure 28 APAC: Market Snapshot
Figure 29 Market Share (2018)
Figure 30 Global Market: Competitive Leadership Mapping (2018)
Figure 31 Labcorp: Company Snapshot (2018)
Figure 32 Eurofins Scientific Se: Company Snapshot (2018)
Figure 33 Charles River Laboratories International: Company Snapshot (2018)
Figure 34 Evotec SE: Company Snapshot (2018)
Figure 35 Thermo Fisher Scientific: Company Snapshot (2018)
Figure 36 Syngene: Company Snapshot (2018)
Figure 37 Jubilant Lifesciences: Company Snapshot (2018)
Figure 38 Genscript Biotech Corporation: Company Snapshot (2018)
Figure 39 Piramal Enterprises Limited: Company Snapshot (2018)



★調査レポート[創薬サービスの世界市場予測:プロセス別(ターゲット選択、検証、リード最適化)、種類別(医薬品化学、DMPK)、薬物タイプ別(生物製剤、小分子)、治療別(腫瘍学、神経学)、企業別(ティア1、2、3)] ( Drug Discovery Services Market by Process (Target Selection, Validation, Lead Optimization), Type (Medicinal Chemistry, DMPK), Drug Type (Biologics, Small Molecules), Therapeutic (Oncology, Neurology), Company (Tier 1, 2, 3) - Global Forecast to 2025 / PH 5682) 販売に関する免責事項
[創薬サービスの世界市場予測:プロセス別(ターゲット選択、検証、リード最適化)、種類別(医薬品化学、DMPK)、薬物タイプ別(生物製剤、小分子)、治療別(腫瘍学、神経学)、企業別(ティア1、2、3)] ( Drug Discovery Services Market by Process (Target Selection, Validation, Lead Optimization), Type (Medicinal Chemistry, DMPK), Drug Type (Biologics, Small Molecules), Therapeutic (Oncology, Neurology), Company (Tier 1, 2, 3) - Global Forecast to 2025 / PH 5682) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆